Tiziana Life Sciences (US:TLSA) Globenewswire·2026-01-09 12:00Core Viewpoint - Tiziana Life Sciences is set to present its lead candidate, intranasal foralumab, at the 9th Annual Neuroscience Innovation Forum, highlighting its potential in treating neurodegenerative conditions [1][3][4]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using alternative drug delivery technologies, particularly intranasal administration [7]. - The company’s lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, showing a favorable safety profile and clinical response in patients [6][7]. Product Details - Foralumab is designed to modulate the immune system and reduce microglial activation in neurodegenerative conditions, specifically targeting non-active secondary progressive multiple sclerosis (na-SPMS) [3][5]. - In an open-label intermediate sized Expanded Access Program, 14 patients with na-SPMS have been dosed, with all showing either improvement or stability of disease within 6 months [5]. Event Participation - CEO Ivor Elrifi will deliver a corporate presentation at the Neuroscience Innovation Forum, which is a key industry event featuring discussions on advancements in therapeutics and neurotechnology [1][3][4]. - Members of Tiziana's senior management team will also be available for one-on-one meetings with investors and stakeholders during the forum [2].